More Videos
- Cowen's "Elan" For Elan
- UBS And Its Guarded Outlook For Merck's Gardasil
- Readers Get Short With Me--Over Amgen
- Biopharma Analyst Musical Chairs
- Abbott, Boston Scientific Stents & Stuff
- A "Short" Story On Amgen
- Merck Muscles In On Migraines
- Boston Scientific: Hurry To The Pre-4th of July Sale On Stents!?
- Credit Suisse Healthier 15: Investors Get Skinny On Fat Fighters
- FDA Delivers One-Two Punch To Merck & Lilly
- PGA Tour: A World (And Ratings) Without Tiger Woods
- Bowyer: The Coming Obama Recession
- Farrell: Signs the Fed Will Defend Dollar?
- Weakening Steel
- Lightning Round: Energy, Big Media and Farm Equipment
- Financial Collapse: Banks Going Quietly Into the Night?
- Cramer: Fashionably Healthy
- Tuesday's Web Extra
- Fast & Furious: Oil, Nascar, Ruby Tuesday...
- El-Erian: Commodity Surge Infecting Everyone
- LSE Shares Soar 11% on Quarterly Revenue Increase
- ExpressJet Airlines Suspends Commercial Operations
- Banks Boost Markets, Strategists Cautious
- GfK Mulls Cash Bid for TNS After WPP Swoop
- Macau's SJM Delays IPO Debut Amid Legal Challenge
- European Shares Set to Join Global Bounce
- South Korea to Ease FX Borrowing in Fresh Flip-Flop
- Australia Consumer Confidence Hits 16-Year Low
 |
CNBC.com |
] and, perhaps, some men and women are celebrating the tenth birthday of Viagra. So, happy birthday little blue pill. But I don't think the folks at Pfizer are popping the champagne corks. Today our stock whiz, Robert Hum, informs me that PFE closed at its lowest level since before the Food and Drug Administration approved Viagra.
The previous nearest closing low occured on October 1st, 1997. Since the world's biggest drug company held its analyst meeting earlier this month, the shares have fallen from $22-and-change to $20-and-change. As Jim Cramer pointed out this morning, though, the high dividend yield might make the stock attractive at this level.
Part of the problem is Pfizer's drug development pipeline. For example, it will not be a headliner at the American College of Cardiology meeting where I'm off to tomorrow. And this year's ACC is not all about Merck [MRK
Loading...
()
] and Schering-Plough's [SGP
Loading...
()
] Vytorin.
Tomorrow Lilly [LLY
Loading...
()
] releases data on whether its bloodthinner, which is on a fast track for possible FDA approval, did a better job than Plavix (Bristol-Myers Squibb and Sanofi-Aventis) at preventing blood clots from forming in stent patients. And then on Monday morning, look for results coming out Monday morning on a weightloss and cholesterol drug from Merck.
See you bright and early on "Squawk Box" at 6 a.m. ET live from McCormick Place.
Questions? Comments?
Del.icio.us
Digg It
Data is a real-time snapshot *Data is delayed at least 15 minutes